Harnessing regulatory T cells for therapeutic purposes.
Level V
Where this comes from
- Record sourced from PubMed, PMID 22543901.
- Also identified by DOI 10.1038/ki.2012.29.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lai and colleagues demonstrate that pretreatment with N,N-dimethylsphingosine (DMS), a naturally occurring sphingosine derivative, provides renoprotection in ischemia/reperfusion injury. This DMS-induced renoprotection was abolished by the administration of agents that suppress regulatory T cells (Tregs) or by anti-CTLA-4 or anti-CD45 monoclonal antibodies, suggesting that Tregs played a critical role. The finding that Tregs are recruited to the kidney via DMS points to the exciting potential of new approaches to harnessing Tregs for therapeutic purposes.
Medical subject headings
- Acute Kidney Injury
- Chemotaxis, Leukocyte
- Immunologic Factors
- Ischemia
- Kidney
- Reperfusion Injury
- Sphingosine
- T-Lymphocytes, Regulatory